ArticleIrish journal of medical science2026
Clinical and hematological parameters associated with omalizumab response in chronic spontaneous urticaria.
Article in Irish journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study aimed to evaluate the clinical efficacy of omalizumab treatment and its effects on hematological, inflammatory, and coagulation parameters, as well as the relationship between these parameters and treatment response, in patients with chronic spontaneous urticaria (CSU) resistant to antihistamines.
methodsThe study included 30 adult CSU patients unresponsive to four-fold dose antihistamine treatment. Patients received 300 mg of subcutaneous omalizumab every 28 days. Clinical response was assessed using the 7-day Urticaria Activity Score (UAS7). Hematological (leukocyte, neutrophil, lymphocyte counts, NLR), inflammatory (CRP, ESR), and coagulation (D-dimer, aPTT, PT, fibrinogen) parameters, as well as total IgE levels, were measured before treatment and at 3 months.
resultsA statistically significant decrease in UAS7 scores was observed after omalizumab treatment (p = 0.001). Treatment resulted in a significant decrease in leukocyte and neutrophil counts, NLR, CRP, ESR, and D-dimer levels, while a slight prolongation of aPTT was observed (p < 0.05). Total IgE, PT, fibrinogen, lymphocyte, monocyte, eosinophil, and basophil counts showed no significant changes. No significant correlation was found between baseline laboratory parameters and clinical response.
conclusionOmalizumab provides clinical improvement in CSU, as well as improvement in parameters reflecting systemic inflammation and coagulation activation. However, our study showed that baseline laboratory values were insufficient to predict treatment response. These findings suggest that the effects of omalizumab are not limited to symptom control but may have more systemic immunomodulatory effects.
Indexed as
Identifiers
42704614What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.